Patents by Inventor Lars Frykberg
Lars Frykberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11814415Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: GrantFiled: October 22, 2021Date of Patent: November 14, 2023Assignee: INTERVACC ABInventors: Bengt Guss, Lars Frykberg, Margareta Flock, Jan-Ingmar Flock, Karl Olov Zachrisson
-
Publication number: 20220048957Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: ApplicationFiled: October 22, 2021Publication date: February 17, 2022Inventors: Bengt GUSS, Lars FRYKBERG, Margareta FLOCK, Jan-Ingmar FLOCK, Karl Olov ZACHRISSON
-
Patent number: 11155585Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: GrantFiled: July 8, 2016Date of Patent: October 26, 2021Assignee: INTERVACC ABInventors: Bengt Guss, Lars Frykberg, Margareta Flock, Jan-Ingmar Flock, Karl Olov Zachrisson
-
Publication number: 20180170974Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: ApplicationFiled: July 8, 2016Publication date: June 21, 2018Inventors: Bengt GUSS, Lars FRYKBERG, Margareta FLOCK, Jan-Ingmar FLOCK, Karl Olov ZACHRISSON
-
Patent number: 9987342Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.Type: GrantFiled: May 13, 2013Date of Patent: June 5, 2018Assignee: INTERVACC ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 9795664Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide compromising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: GrantFiled: December 4, 2015Date of Patent: October 24, 2017Assignee: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 9333252Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: GrantFiled: May 25, 2011Date of Patent: May 10, 2016Assignee: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Publication number: 20160082096Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide compromising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: ApplicationFiled: December 4, 2015Publication date: March 24, 2016Inventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Publication number: 20140220064Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.Type: ApplicationFiled: May 13, 2013Publication date: August 7, 2014Inventors: Bengt GUSS, Jan-Ingmar FLOCK, Lars FRYKBERG, Margareta FLOCK
-
Publication number: 20130236469Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: ApplicationFiled: May 25, 2011Publication date: September 12, 2013Applicant: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 8404245Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. Equi and subsp. Zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. Zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component. The antigens used are EAG, FNZ, SFS, SEC and ScLC.Type: GrantFiled: October 10, 2003Date of Patent: March 26, 2013Assignee: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Karin Jacobsson, Kenneth Janzon, Lars Frykberg, Margareta Flock, Rune Bergman
-
Publication number: 20120225079Abstract: An antigenic composition comprises at least one antigen, wherein said at least one antigen comprises at least part of a protein selected from EndoSe of Streptococcus equi subsp. Equi, EndoSz of Streptococcus equi subsp. zooepidemicus, and Endo S of Streptococcus pyogenes, and wherein said at least part of said protein comprises at least one antigenic epitope. A vaccine composition comprising the antigenic composition as immunizing component, methods for producing the antigeninc composition and the vaccine composition, use of the vaccine composition for prophylactic and therapeutic treatment, and an antibody preparation comprising monoclonal or polyclonal antibodies specific for an antigen or antigens of the antigenic composition are also disclosed.Type: ApplicationFiled: November 11, 2010Publication date: September 6, 2012Applicant: INTERVACC ABInventors: Bengt Guss, Lars Frykberg, Jan-Ingmar Flock, Margareta Flock
-
Publication number: 20110020403Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.Type: ApplicationFiled: December 12, 2008Publication date: January 27, 2011Inventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 7160990Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.Type: GrantFiled: March 23, 2004Date of Patent: January 9, 2007Assignee: Biostapro ABInventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
-
Publication number: 20060140980Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. Equi and subsp. Zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. Zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component. The antigens used are EAG, FNZ, SFS, SEC and ScLC.Type: ApplicationFiled: October 10, 2003Publication date: June 29, 2006Applicant: Beng GussInventors: Bengt Guss, Jan-Ingmar Flock, Karin Jacobsson, Kenneth Janzon, Lars Frykberg, Margareta Flock, Rune Bergman
-
Publication number: 20040209326Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.Type: ApplicationFiled: March 23, 2004Publication date: October 21, 2004Inventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
-
Patent number: 6733758Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.Type: GrantFiled: April 1, 1999Date of Patent: May 11, 2004Inventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
-
Publication number: 20040014178Abstract: Von Willebrand factor binding proteins and polypeptides from Staphylococci are disclosed. Further, recombinant DNA molecules coding for said proteins and peptides, plasmids, phages and phagemids comprising the DNA molecules, and microorganisms and microorganisms comprising the recombinant DNA molecules or the plasmids, phages and phagemids are described. Additionally, a method of producing von Willebrand factor binding protein or polypeptide, a method of blocking the adherence of a Staphylococcus to surfaces, immobilized proteins, antigodies, immunogens, purifications methods and determination of the presence of von Willebrand factor in a complex solution, are disclosed.Type: ApplicationFiled: July 2, 2003Publication date: January 22, 2004Inventors: Bengt Guss, Lars Frykberg, Martin Nilsson, Karin Jacobsson, Joakim Ahlen
-
Publication number: 20030165527Abstract: The present invention is concerned with a novel fibronectin-binding protein of Streptococcus equi, to a DNA fragment encoding this protein, to host cells and vectors containing said DNA fragment and to methods to produce said protein based on recombinant DNA technology.Type: ApplicationFiled: October 11, 2002Publication date: September 4, 2003Inventors: Bengt Guss, Karin Jacobsson, Lars Frykberg, Hans Lindmark
-
Patent number: 6548639Abstract: A recombinant DNA molecule coding for a protein expressed by a Staphylococcus aureus bacterium, comprising the nucleotide sequence SEQ ID NO:1 or a homologous sequence, or a partial or homologous sequence of SEQ ID NO:1 coding for a polypeptide fragment comprising at least 15 amino acid residues, is described. Further, a protein expressed by such a bacterium or a polypeptide fragment comprising at least 15 amino acid residues, comprising the amino acid sequence SEQ ID NO:2 binds IgG and apolipoprotein H. Examples of the polypeptide fragments comprise the SEQ ID NO:3 through 6. These proteins and polypeptide fragments may be coupled to an inert carrier or matrix. Vectors comprising such a DNA molecule or the corresponding RNA molecule, and antibodies specifically binding to a polypeptide having an amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, are also disclosed.Type: GrantFiled: May 12, 2000Date of Patent: April 15, 2003Assignee: Biostapro ABInventors: Lars Frykberg, Karin Jacobsson